- Home
- TIL vs INBX Comparison
TIL vs INBX Comparison
Compare TIL & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- INBX
- Stock Information
- Founded
- TIL 2018
- INBX 2010
- Country
- TIL United States
- INBX United States
- Employees
- TIL N/A
- INBX N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- INBX Health Care
- Exchange
- TIL Nasdaq
- INBX Nasdaq
- Market Cap
- TIL 171.7M
- INBX 190.2M
- IPO Year
- TIL 2021
- INBX 2020
- Fundamental
- Price
- TIL $22.12
- INBX $12.56
- Analyst Decision
- TIL Strong Buy
- INBX Hold
- Analyst Count
- TIL 4
- INBX 1
- Target Price
- TIL $114.00
- INBX N/A
- AVG Volume (30 Days)
- TIL 83.9K
- INBX 88.8K
- Earning Date
- TIL 03-20-2025
- INBX 11-14-2024
- Dividend Yield
- TIL N/A
- INBX 6.77%
- EPS Growth
- TIL N/A
- INBX N/A
- EPS
- TIL N/A
- INBX 119.38
- Revenue
- TIL N/A
- INBX $1,568,000.00
- Revenue This Year
- TIL N/A
- INBX N/A
- Revenue Next Year
- TIL N/A
- INBX N/A
- P/E Ratio
- TIL N/A
- INBX $0.11
- Revenue Growth
- TIL N/A
- INBX 19.24
- 52 Week Low
- TIL $9.62
- INBX $10.80
- 52 Week High
- TIL $92.00
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- TIL 48.67
- INBX 42.38
- Support Level
- TIL $19.00
- INBX $12.08
- Resistance Level
- TIL $25.80
- INBX $13.60
- Average True Range (ATR)
- TIL 2.19
- INBX 0.76
- MACD
- TIL 0.22
- INBX 0.05
- Stochastic Oscillator
- TIL 45.88
- INBX 20.87
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.